【bismuth shot size for ducks】Who Has Been Buying Pulmonx Corporation (NASDAQ:LUNG) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand,bismuth shot size for ducks we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So shareholders might well want to know whether insiders have been buying or selling shares in

Pulmonx Corporation

(

NASDAQ:LUNG

).

What Is Insider Buying?

It's quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, such insiders must disclose their trading activities, and not trade on inside information.

Insider transactions are not the most important thing when it comes to long-term investing. But equally, we would consider it foolish to ignore insider transactions altogether. For example, a Columbia University

study

found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.

See our latest analysis for Pulmonx

The Last 12 Months Of Insider Transactions At Pulmonx

Over the last year, we can see that the biggest insider purchase was by Independent Chairperson of the Board Dana Mead for US$500k worth of shares, at about US$19.00 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$69.02. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

In the last twelve months Pulmonx insiders were buying shares, but not selling. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume

Pulmonx is not the only stock that insiders are buying. For those who like to find

winning investments

this

free

list of growing companies with recent insider purchasing, could be just the ticket.

Insiders at Pulmonx Have Bought Stock Recently

Over the last three months, we've seen significant insider buying at Pulmonx. Not only was there no selling that we can see, but they collectively bought US$1.5m worth of shares. This makes one think the business has some good points.

Does Pulmonx Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Pulmonx insiders own 5.5% of the company, currently worth about US$135m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

Story continues

So What Does This Data Suggest About Pulmonx Insiders?

It is good to see recent purchasing. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest Pulmonx insiders are well aligned, and quite possibly think the share price is too low. Nice! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted

2 warning signs for Pulmonx

you should be aware of.

Of course

Pulmonx may not be the best stock to buy

. So you may wish to see this

free

collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content?

Get in touch

with us directly.

Alternatively, email editorial-team (at) simplywallst.com.

View comments